Vir Biotechnology, Inc. (Nasdaq: VIR) will present topline Phase 3 ECLIPSE-1 results for its investigational combination of elebsiran and tobevibart in chronic hepatitis delta at the American Association for the Study of Liver Diseases’ Liver Meeting on 8 November 2026. The late-breaking presentation will provide pivotal clinical evidence comparing monthly subcutaneous treatment with a deferred-treatment strategy, forming part of a three-trial programme intended to support potential regulatory submissions.
The announcement, issued on 5 November, confirms that the study’s primary endpoint findings will be presented at 2:15 p.m. Mountain Time in Denver, Colorado. Vir Biotechnology has also scheduled an investor conference call for 9 November to discuss the Phase 3 readout and expanded results from its earlier Phase 2 SOLSTICE investigation.
The results remain undisclosed as of 6 November, making the forthcoming presentation an important near-term development rather than evidence of a successful trial. Previous SOLSTICE findings have demonstrated substantial hepatitis delta viral suppression in treated participants, but the Phase 3 programme must establish the efficacy and safety of the combination in a controlled registrational setting.
The competitive context has also changed. With Gilead Sciences’ Hepcludex receiving United States approval in May 2026, Vir Biotechnology is developing a potential alternative in a market where treatment availability, dosing convenience and the durability of viral suppression are increasingly important.
What will the Phase 3 ECLIPSE-1 study reveal about elebsiran and tobevibart in chronic hepatitis delta?
ECLIPSE-1 is a randomised, open-label Phase 3 clinical trial comparing elebsiran and tobevibart with deferred treatment in adults with chronic hepatitis delta infection. The study completed enrolment in November 2025 and forms the first part of Vir Biotechnology’s broader registrational programme.
The trial was designed to enrol approximately 124 participants, with patients assigned in a two-to-one ratio to the investigational combination or a deferred-treatment strategy. Eligible participants include adults with chronic hepatitis delta and either non-cirrhotic liver disease or compensated cirrhosis, subject to the study’s clinical criteria.
The investigational regimen consists of two separate sequential subcutaneous injections administered every four weeks. The combination is intended to reduce hepatitis delta viral activity through complementary mechanisms targeting hepatitis B surface antigen and its role in maintaining hepatitis delta infection.
The registered study framework includes a virological and biochemical primary efficacy assessment, combining undetectable hepatitis delta virus RNA with normalisation of alanine aminotransferase, a liver enzyme associated with hepatocellular injury. The active-treatment assessment is specified at Week 48, while the deferred-treatment comparison incorporates an earlier assessment period.
This design requires careful interpretation because the two treatment strategies differ in timing as well as exposure to the investigational medicines. The forthcoming results will need to show how the prespecified analysis accounts for these differences and what the observed effect means clinically.
The open-label design also introduces potential limitations. Although laboratory measurements such as viral RNA are less susceptible to subjective assessment than patient-reported outcomes, knowledge of treatment allocation can affect supportive care, monitoring and other aspects of clinical management.
The trial includes safety assessments that will help determine whether sustained treatment is feasible in the intended population. This is important because patients with chronic hepatitis delta may already have significant liver disease and could require treatment over extended periods.
Vir Biotechnology has not disclosed whether the trial met its primary endpoint, the response rates in either group or the statistical results. Those findings are expected during the scheduled late-breaking presentation.
Why is undetectable hepatitis delta virus RNA a central measure of treatment effectiveness?
Hepatitis delta virus requires hepatitis B virus infection to establish and maintain infection because it depends on hepatitis B surface antigen for its life cycle.
Chronic hepatitis delta is associated with particularly aggressive liver disease. Patients face increased risks of cirrhosis, liver decompensation, hepatocellular carcinoma and liver-related death compared with many individuals living with hepatitis B infection alone.
Reducing hepatitis delta viral replication is therefore an important therapeutic objective. Clinical studies commonly examine hepatitis delta RNA and liver enzymes to assess whether investigational treatments are producing meaningful antiviral activity.
An undetectable viral RNA result, often described as target not detected, represents a more stringent laboratory finding than a reduction in viral load that remains measurable. However, the clinical significance of either outcome depends on the assay, treatment duration and persistence of suppression.
Alanine aminotransferase normalisation provides a complementary measure because it reflects improvement in a biochemical marker of liver injury. A composite endpoint combining viral suppression with enzyme normalisation therefore investigates both antiviral and biochemical responses.
The distinction is particularly relevant to Vir Biotechnology’s programme. Earlier studies have reported substantial reductions in hepatitis delta RNA, but the ECLIPSE programme is intended to establish whether the combination delivers reproducible responses in a larger controlled setting.
An encouraging virological result would strengthen the evidence supporting further regulatory development, particularly if accompanied by appropriate safety and biochemical findings.
However, even a statistically significant virological response would not automatically establish that treatment prevents cirrhosis, liver cancer or mortality. Those outcomes depend on longer-term clinical evidence and the relationship between sustained viral suppression and disease progression.
The forthcoming trial presentation will therefore need to distinguish the observed antiviral effect from any broader claims concerning long-term clinical benefit.
How do the published Phase 2 SOLSTICE results support Vir Biotechnology’s clinical rationale?
The Phase 2 SOLSTICE trial provides the most important previously published clinical evidence supporting elebsiran and tobevibart in chronic hepatitis delta.
The randomised, open-label study involved 65 participants, comparing monthly administration of the two-drug combination with tobevibart monotherapy given every two weeks.
Results published in the New England Journal of Medicine showed that 47% of participants receiving the combination achieved the study’s combined virological and alanine aminotransferase response endpoint at Week 24. The corresponding proportion was 70% among those receiving tobevibart monotherapy.
These findings demonstrate why different endpoints must be examined separately. Although the monotherapy arm produced a higher combined response rate at that particular assessment, the combination showed important activity on other virological measures.
At Week 48, undetectable hepatitis delta RNA was reported in 66% of participants receiving elebsiran and tobevibart, compared with 48% receiving tobevibart alone. The combination was also associated with substantial reductions in hepatitis B surface antigen.
Approximately 91% of combination-treated participants had hepatitis B surface antigen concentrations below 10 IU/mL at Week 48, compared with 21% in the monotherapy group.
These results supported the biological rationale for pursuing a two-drug regimen that addresses different aspects of the viral life cycle. However, the study was not designed to establish clinical superiority against an approved hepatitis delta treatment.
The investigators also reported adverse events in both treatment groups. Through Week 48, treatment-emergent adverse events were reported in 81% of combination recipients and 94% of participants receiving monotherapy, with influenza-like illness and chills among the commonly described events.
The safety findings supported continued evaluation, but the small sample size limited the ability to identify uncommon complications or establish the long-term benefit-risk balance.
An important strength of SOLSTICE is that its Week 48 findings were peer-reviewed, providing a more detailed evidence base than an isolated company presentation. ECLIPSE-1 must now determine whether the combination’s activity is reproducible in a larger pivotal population and appropriate for regulatory consideration.
What do the Week 72 and Week 96 SOLSTICE findings suggest about response durability?
Vir Biotechnology has continued following participants in SOLSTICE to investigate whether viral suppression persists during longer treatment.
In January 2026, the company reported that 77% of evaluable combination-treated participants, representing 24 of 31 patients, had undetectable hepatitis delta RNA at Week 72.
Among the 24 combination-treated participants who had reached Week 96, 21 had undetectable viral RNA, equivalent to 88%. By comparison, the company reported undetectable viral RNA in 46% of the 24 monotherapy recipients evaluated at that time.
These results provide an encouraging longer-term antiviral signal. However, they must be interpreted according to the number of participants who had reached each assessment, rather than presented as response rates for every originally enrolled patient.
The Week 96 percentage is particularly sensitive to the size and composition of the evaluable population. A result involving 21 of 24 participants does not establish that the same proportion would be maintained among all patients entering a larger study.
The observed results also reflect outcomes during ongoing treatment. They do not establish that patients would maintain viral suppression after stopping therapy or that the regimen produces a functional cure.
For chronic hepatitis delta, durability is important because sustained viral suppression may be relevant to preventing continued liver injury. Nevertheless, the relationship between treatment duration, hepatitis B surface antigen reduction and long-term clinical outcomes requires further investigation.
Vir Biotechnology plans to present expanded Week 96 SOLSTICE results at the Liver Meeting on 8 November. A separate translational analysis examining changes in intrahepatic natural killer cells is scheduled for 7 November.
These additional presentations may provide information about the consistency of viral suppression and biological effects of the regimen. However, exploratory immune findings should not be treated as independent evidence of improved liver outcomes.
How do elebsiran and tobevibart target different stages of hepatitis delta infection?
The combination uses two investigational medicines with complementary biological mechanisms.
Elebsiran, previously identified as VIR-2218, is a small interfering RNA therapeutic licensed from Alnylam Pharmaceuticals. It is designed to target hepatitis B virus RNA transcripts, reducing production of hepatitis B surface antigen.
This mechanism is relevant because hepatitis delta depends on hepatitis B surface antigen to form infectious viral particles and sustain infection.
Tobevibart, previously known as VIR-3434, is an investigational broadly neutralising monoclonal antibody that targets hepatitis B surface antigen. It is designed to inhibit viral entry into liver cells and reduce circulating viral and subviral particles.
Vir Biotechnology has engineered the antibody’s Fc region to support immune engagement and the clearance of hepatitis B surface antigen-containing immune complexes. The molecule also incorporates half-life extension technology intended to support less frequent dosing.
By combining the two mechanisms, the company aims to reduce hepatitis B surface antigen production while also targeting circulating antigen and viral entry.
This strategy differs from directly targeting only one component of the hepatitis delta replication cycle. The biological hypothesis is that multiple complementary actions may produce more sustained suppression than a single mechanism.
However, mechanistic complementarity does not establish superior clinical efficacy. The published SOLSTICE findings showed different response patterns across virological and biochemical endpoints, highlighting the complexity of interpreting combination treatment effects.
ECLIPSE-1 is intended to provide more definitive evidence concerning whether the regimen produces a clinically and statistically persuasive benefit within the proposed registrational framework.
The monthly administration schedule could also offer a convenience advantage relative to more frequent injectable treatment, but actual patient preference and adherence benefits would require appropriate evaluation.
Why does the US approval of Hepcludex change the competitive interpretation of ECLIPSE-1?
Gilead Sciences’ Hepcludex, containing bulevirtide, received FDA approval on 22 May 2026 for chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis.
The medicine had already established a regulatory presence in Europe, where its authorised use includes patients with chronic hepatitis delta and compensated liver disease.
The United States approval is important because it changes the treatment environment in which Vir Biotechnology’s development programme will ultimately compete.
ECLIPSE-1 was designed to compare the investigational regimen with deferred treatment in regions where bulevirtide was unavailable or its use was limited. That design reflected the treatment landscape when the study was initiated.
However, the existence of an approved United States therapy creates an additional question for clinicians and payers: how does elebsiran and tobevibart compare with the treatment options now available?
A positive result against deferred treatment could establish an important treatment effect, but it would not directly demonstrate superiority or non-inferiority against Hepcludex.
This is where Vir Biotechnology’s broader ECLIPSE programme becomes commercially relevant. ECLIPSE-2 and ECLIPSE-3 are designed to generate evidence involving bulevirtide, addressing clinical questions that cannot be resolved by ECLIPSE-1 alone.
The distinction also affects reimbursement. Payers evaluating a future approved alternative may require evidence concerning comparative virological activity, dosing burden, safety and treatment duration.
Monthly administration may be attractive relative to more frequent injections, but convenience will need to be balanced against the clinical evidence and economic terms associated with each treatment.
The competitive position of elebsiran and tobevibart will therefore depend on the combined findings from all three ECLIPSE studies, not only the first pivotal readout.
How will ECLIPSE-2 and ECLIPSE-3 strengthen the global regulatory evidence package?
Vir Biotechnology’s ECLIPSE programme consists of three controlled studies examining different patient populations and treatment comparisons.
ECLIPSE-1 evaluates the combination against deferred treatment, providing the first pivotal assessment expected to support the programme’s global regulatory strategy.
ECLIPSE-2 investigates patients who have not achieved adequate viral suppression with bulevirtide. It evaluates the potential benefit of switching from the established treatment to elebsiran and tobevibart.
That study addresses a clinically important population because not every patient receiving an approved antiviral therapy achieves the desired level of suppression.
ECLIPSE-3 compares the investigational combination directly with bulevirtide in patients who have not previously received the approved drug. The study is intended to generate evidence relevant to treatment positioning and reimbursement in markets where bulevirtide is available.
The company expects topline results from ECLIPSE-2 and ECLIPSE-3 during the first quarter of 2027. These findings are expected to contribute to a comprehensive regulatory submission package alongside ECLIPSE-1.
The three-study structure provides a broader evaluation than a single comparator would allow. It examines initial treatment, an inadequate-response setting and direct comparison with an established therapy.
However, the trials will still need to be assessed separately according to their prespecified endpoints and statistical analysis plans. Positive findings in one population cannot automatically establish efficacy in another.
For regulators, consistency across the programme could strengthen confidence in the regimen’s antiviral activity and safety. For clinicians, the comparative studies may be particularly valuable in determining which patients are most likely to benefit.
What does Vir Biotechnology’s latest financial position mean for its hepatitis delta programme?
Vir Biotechnology reported approximately US$901.3 million in cash, cash equivalents and investments at 30 September 2026, a decrease of US$106.5 million during the third quarter.
The figure excluded US$90 million in cash consideration subsequently received through the company’s oncology collaboration with Gilead Sciences. That transaction included a US$65 million upfront payment and a US$25 million equity investment, with additional contingent milestone payments possible.
Vir Biotechnology reported third-quarter research and development expenditure of US$80 million, compared with US$151.5 million a year earlier. The year-earlier period included a substantial non-recurring milestone expense, meaning the reduction should not be interpreted solely as lower underlying development activity.
The company’s quarterly net loss narrowed to US$96.3 million from US$163.1 million. Management continues to expect its resources to support operations into the second half of 2028, based on current plans.
This funding position is important as Vir Biotechnology approaches several potential development milestones across infectious disease and oncology.
The company’s portfolio includes investigational T-cell engager programmes, including VIR-5500, being developed with Astellas Pharma for prostate cancer. Its broader strategy therefore requires balancing investment across multiple clinical programmes.
The hepatitis delta programme also has a defined commercial partnership structure. Norgine holds licensed commercial rights to the elebsiran and tobevibart combination in Europe, Australia and New Zealand, while Vir Biotechnology retains rights in the United States and certain other markets.
These arrangements could support future commercial preparation, although the value of the partnership will depend on successful development and regulatory approval.
Vir Biotechnology shares closed at US$11.02 on 5 November 2026, declining 6.37% during the session. The stock was approximately 6.2% lower over the preceding five trading sessions and about 6.5% lower over the preceding month, while remaining substantially above its level at the beginning of the year.
The reported 52-week trading range was US$4.82 to US$12.19, with a market capitalisation of approximately US$1.8 billion. These figures indicate that investors have assigned significant value to the company’s clinical portfolio, but the near-term movement also illustrates sensitivity ahead of major readouts.
The 5 November share decline preceded disclosure of the actual ECLIPSE-1 clinical results and cannot be interpreted as a reaction to an outcome that had not been published.
What will determine whether the ECLIPSE-1 results support a competitive hepatitis delta treatment?
The 8 November presentation will provide the first major answer to whether the investigational combination has achieved its pivotal trial objectives.
The most important findings will include the proportion of patients achieving the specified virological and biochemical response, the magnitude of the difference between study groups and the statistical certainty associated with that result.
Safety will be equally important, particularly among participants with compensated cirrhosis or other clinically relevant liver disease characteristics. Investigators will need to report adverse events, treatment discontinuations and the consistency of responses across the studied population.
The additional SOLSTICE presentations may provide useful information about longer-term suppression and immune effects, but those findings will need to remain distinct from the controlled Phase 3 results.
Vir Biotechnology’s investor call on 9 November will provide an opportunity for management to explain the readout, the remaining ECLIPSE programme and its expected regulatory strategy.
A favourable ECLIPSE-1 result could strengthen the rationale for future submissions, but it would not constitute marketing approval. The company would still need to complete the relevant evidence package and secure decisions from applicable regulators.
With Hepcludex now approved in the United States and established in Europe, the commercial test extends beyond demonstrating antiviral activity. Vir Biotechnology must also establish where its monthly combination offers meaningful value relative to available treatment.
The ECLIPSE-1 readout will therefore determine whether the programme has crossed an important clinical threshold. ECLIPSE-2 and ECLIPSE-3 will help determine how that evidence translates into treatment selection, reimbursement and the competitive positioning of elebsiran and tobevibart.
